Skip to main content

In this Dec. 19, 2014 photo, Dr. George Koob, director of the National Institute on Alcohol Abuse and Alcoholism, left, and NIAAA scientist Dr. Lorenzo Leggio stand in their bar-lab.Cliff Owen/The Associated Press

The tequila sure looks real, so do the beer taps. Inside the hospital at the U.S. National Institutes of Health, researchers are testing a possible new treatment to help heavy drinkers cut back – using a replica of a fully stocked bar.

The idea: Sitting in the dimly lit bar-laboratory should cue the volunteers' brains to crave a drink, and help determine if the experimental pill counters that urge.

True, there's no skunky bar odour; these bottles are filled with coloured water. The real alcohol is locked in the hospital pharmacy, ready to send over for the extra temptation of smell – and to test how safe the drug is if people drink anyway.

"The goal is to create almost a real-world environment, but to control it very strictly," said lead researcher Dr. Lorenzo Leggio, who is testing how a hormone named ghrelin that sparks people's appetite for food also affects their desire for alcohol, and if blocking it helps.

Amid all the yearly resolutions to quit, alcohol-use disorders affect about 17 million Americans, and only a small fraction receives treatment. There's no one-size-fits-all therapy, and the NIH is spurring a hunt for new medications that target the brain's addiction cycle in different ways – and to find out which options work best in which drinkers.

"Alcoholics come in many forms," explained Dr. George Koob, director of NIH's National Institute of Alcohol Abuse and Alcoholism, which has published new online guides, at, explaining who's at risk and what can help.

What's the limit? The NIAAA says "low-risk" drinking means no more than four drinks in any single day and no more than 14 in a week for men, and no more than three drinks a day and seven a week for women.

Genes play a role in who's vulnerable to crossing the line into alcohol abuse. So do environmental factors, such as getting used to drinking a certain amount, not to mention how your own brain's circuitry adapts.

Treatment can range from inpatient rehab and 12-step programs to behavioural therapy and the few medications available today. Koob, who specializes in the neurobiology of alcohol, says it usually takes a combination and, ultimately, "you have to change your life."

Yet a recent review for the U.S. Agency for Healthcare Research and Quality estimated that less than a third of Americans who need treatment get it, and of those, less than 10 per cent receive medications.

Three drugs are approved by the U.S. Food and Drug Administration to treat alcohol abuse. One, naltrexone, blocks alcohol's feel-good sensation by targeting receptors in the brain's reward system – if people harbour a particular gene. The anti-craving pill acamprosate appears to calm stress-related brain chemicals in certain people. The older Antabuse works differently, triggering nausea and other aversive symptoms if people drink while taking it.

Recent research suggests a handful of drugs used for other disorders also show promise:

Scientists at the Scripps Research Institute found the epilepsy drug gabapentin reduced relapses in drinkers who had recently quit, and improved cravings, mood and sleep by targeting an emotion-related brain chemical.

A study by NIAAA and five medical centres found the anti-smoking drug Chantix may help alcohol addiction, too, by reducing heavy drinkers' cravings.

And University of Pennsylvania researchers found the epilepsy drug topiramate helped heavy drinkers cut back, if they have a particular gene variation mostly found in people of European descent.

Back in NIH's bar-lab, one of about a dozen versions around the United States, the focus is on ghrelin, the hormone produced in the stomach that controls appetite via receptors in the brain. It turns out there's overlap between receptors that fuel overeating and alcohol craving in the brain's reward system, explained NIAAA's Leggio.

In a study published this fall, his team gave 45 heavy-drinking volunteers different doses of ghrelin, and their urge to drink rose along with the extra hormone.

Now Leggio is testing whether blocking ghrelin's action also blocks those cravings, using an experimental Pfizer drug originally developed for diabetes but never sold. The main goal of this first-step study is to ensure mixing alcohol with the drug is safe. But researchers also measure cravings as volunteers, hooked to a blood-pressure monitor in the tiny bar-lab, smell a favourite drink. Initial safety results are expected this spring.

"Our hope is that down the line, we might be able to do a simple blood test that tells if you will be a naltrexone person, an acamprosate person, a ghrelin person," Koob said.

Interact with The Globe